Fig. 3
From: Efficacy and safety of a novel naltrexone treatment for dry eye in type 1 diabetes
Efficacy of NTX-001 to restore tear secretion over a period of 10 days. Tear secretion (mm) was measured (2–4 h, 96 h, and 240 h) in the treated right eye of rats receiving Vigamox® + NTX, NTX-001 formulation or buffer; normal (N) baseline and T1D baseline values are included for comparison. Values represent means ± SEM; significantly different from T1D baseline values at p < 0.05 (*), p < 0.01 (**), p < 0.001 (***), and p < 0.0001 (****).Significant difference between Vigamox+NTX and NTX-001 was noted at 96 h (+, p < 0.05)